|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CPN1 |
Gene summary for CPN1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CPN1 | Gene ID | 1369 |
| Gene name | carboxypeptidase N subunit 1 | |
| Gene Alias | CPN | |
| Cytomap | 10q24.2 | |
| Gene Type | protein-coding | GO ID | GO:0006508 | UniProtAcc | P15169 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1369 | CPN1 | NAFLD1 | Human | Liver | NAFLD | 1.81e-02 | 4.42e-01 | -0.04 |
| 1369 | CPN1 | HCC1_Meng | Human | Liver | HCC | 1.14e-43 | 3.09e-02 | 0.0246 |
| 1369 | CPN1 | Pt14.a | Human | Liver | HCC | 1.03e-02 | 3.06e-01 | 0.0169 |
| 1369 | CPN1 | S014 | Human | Liver | HCC | 6.53e-12 | 5.74e-01 | 0.2254 |
| 1369 | CPN1 | S015 | Human | Liver | HCC | 3.07e-23 | 1.02e+00 | 0.2375 |
| 1369 | CPN1 | S016 | Human | Liver | HCC | 1.27e-17 | 6.87e-01 | 0.2243 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00485457 | Liver | NAFLD | response to steroid hormone | 75/1882 | 339/18723 | 3.44e-11 | 1.12e-08 | 75 |
| GO:00513846 | Liver | NAFLD | response to glucocorticoid | 36/1882 | 148/18723 | 3.88e-07 | 2.52e-05 | 36 |
| GO:00319606 | Liver | NAFLD | response to corticosteroid | 37/1882 | 167/18723 | 3.03e-06 | 1.23e-04 | 37 |
| GO:004854522 | Liver | HCC | response to steroid hormone | 206/7958 | 339/18723 | 6.81e-12 | 2.92e-10 | 206 |
| GO:005160412 | Liver | HCC | protein maturation | 171/7958 | 294/18723 | 3.80e-08 | 8.30e-07 | 171 |
| GO:005138421 | Liver | HCC | response to glucocorticoid | 90/7958 | 148/18723 | 5.18e-06 | 6.47e-05 | 90 |
| GO:003196021 | Liver | HCC | response to corticosteroid | 98/7958 | 167/18723 | 1.73e-05 | 1.87e-04 | 98 |
| GO:001648511 | Liver | HCC | protein processing | 121/7958 | 225/18723 | 4.01e-04 | 2.71e-03 | 121 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CPN1 | SNV | Missense_Mutation | c.416C>T | p.Ala139Val | p.A139V | P15169 | protein_coding | tolerated(0.1) | benign(0.011) | TCGA-A2-A0EM-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| CPN1 | SNV | Missense_Mutation | c.1183G>A | p.Asp395Asn | p.D395N | P15169 | protein_coding | tolerated(0.56) | benign(0.034) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | |
| CPN1 | SNV | Missense_Mutation | c.836T>C | p.Ile279Thr | p.I279T | P15169 | protein_coding | tolerated(0.15) | probably_damaging(0.997) | TCGA-BH-A204-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CPN1 | insertion | Nonsense_Mutation | novel | c.802_803insCAAGCTGTATTTAGCCAGAAGTTTCAGCCTTCTAGGTGA | p.Gly268delinsAlaSerCysIleTerProGluValSerAlaPheTerValSer | p.G268delinsASCI*PEVSAF*VS | P15169 | protein_coding | TCGA-A8-A09D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
| CPN1 | SNV | Missense_Mutation | c.1031G>A | p.Gly344Glu | p.G344E | P15169 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| CPN1 | SNV | Missense_Mutation | novel | c.8A>G | p.Asp3Gly | p.D3G | P15169 | protein_coding | tolerated(0.24) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CPN1 | SNV | Missense_Mutation | c.370N>G | p.His124Asp | p.H124D | P15169 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1M6-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| CPN1 | SNV | Missense_Mutation | novel | c.8N>T | p.Asp3Val | p.D3V | P15169 | protein_coding | tolerated(0.07) | benign(0.017) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
| CPN1 | SNV | Missense_Mutation | novel | c.7N>A | p.Asp3Asn | p.D3N | P15169 | protein_coding | tolerated(0.22) | benign(0) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
| CPN1 | SNV | Missense_Mutation | c.1189G>C | p.Glu397Gln | p.E397Q | P15169 | protein_coding | tolerated(0.43) | benign(0.001) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1369 | CPN1 | ENZYME, PROTEASE, DRUGGABLE GENOME | inhibitor | 252166856 | ||
| 1369 | CPN1 | ENZYME, PROTEASE, DRUGGABLE GENOME | inhibitor | 252166875 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |